Background: The better use of new and emerging data streams to understand the epidemiology of infectious disease and to inform and evaluate antimicrobial stewardship improvement programmes is paramount in the global fight against antimicrobial resistance.
Introduction
Health systems are generating increasing volumes of routine clinical data as individuals interact with healthcare services. Strategies for surveillance of antimicrobial resistance (AMR) and to address emergent problems require intelligent use of these new and emerging data streams to augment understanding of the epidemiology of infectious disease nationally, and contribute to the global public health effort against the threat of AMR. [1] [2] [3] In the UK, the AMR strategy (2013-18) defined as a key action 'better access to and use of surveillance data', and recognized that current information on the impact of antimicrobial use on patient outcome and development of resistance was limited. 4 In response the Scottish Antimicrobial Management of Resistance Action Plan, recognizing the importance of informatics, called for development of an NHS Scotland Infection Intelligence Platform (IIP) to empower clinicians and healthcare systems to measure the intended and unintended consequences of interventions to prevent and treat infections. 5 The IIP is an ambitious programme that aims to move to a position of enhanced connectivity of datasets to achieve a comprehensive, dynamic and responsive integrated informatics V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
resource to support improvements in outcomes for patients with, or at risk of, infection. 6 Underpinning this was our aim to create a more collegiate community of infection control and stewardship clinicians, supported by IIP, to deliver better informed clinical decisions, guide national policy and contribute to the global AMR effort. In this paper, we describe our early experiences and results in developing the IIP.
Methods
The AMR policy frameworks provided the stimulus and environment to build a broad coalition of clinicians and national stakeholders to co-create the vision for IIP-'to improve patient outcomes and reduce harm from infection through innovative data integration to support clinicians within the NHS in Scotland'. Led by the Scottish Antimicrobial Prescribing Group (SAPG) and supported by NHS National Services Scotland (NSS), stakeholders from policy, clinical practice and academia produced a proposal describing the benefits of, and target deliverables from, the creation of a national infection informatics resource. Initial funding was secured from Scottish Government for the initial IIP programme from 2013 to 2017. The programme focused on three areas: (i) technical platform development to enable linking of varied NHS datasets to enhance surveillance capability, analysis and responsiveness; (ii) implementation of proportionate information governance best practices to enable efficient, agile response to important clinical questions; and (iii) generation of new evidence for improved clinical practice through clinical exemplar studies using the IIP.
Record linkage capability was core to the IIP development. In NHS Scotland all individuals have a unique patient identifier [the Community Health Index (CHI) number], which enables records for the same patient to be linked across multiple health records, capturing a patient's pathway through the healthcare system. 7 NHS NSS hosts a range of national health datasets that were the initial focus for IIP. On review, these datasets contained a wealth of information applicable to infection, but these were poorly connected and underused by the diverse clinical communities who could benefit from better integration. Supported by a clinical user community prioritization exercise, eight datasets were initially selected for inclusion within the IIP (Table 1) .
Data access is controlled through NSS Information Governance Procedures ensuring NSS analysts can only access IIP data views for which they have underlying dataset approval. In addition, generic ethics and privacy approval for the conduct of linkage studies under the programme was secured with documentation of analyses for audit purposes.
Results
The IIP is hosted within the NSS Corporate Data Warehouse (CDW), the central repository for national datasets, connected by a standardized set of common dimensions. IIP technical developments enabled the creation of virtual 'simplified views' of each IIP dataset, e.g. the SMR01 view joins over 36 tables in a flat-like structure to expose 50 variables that meet the majority of infection analysis requirements. Analysts run queries across these views within the IIP statistical platform. Further functionality includes a cohort solution enabling definition and extraction of patient cohorts from across datasets, storable for repeated use. 8 The main benefits arising from the IIP technical build have been: improved data security and reduced errors with fewer data extracts (reducing human errors in multiple file extraction and subsequent linkage) as statistical packages process data directly in the CDW; better flexibility in running repeated linkages and refreshing reporting for common queries; and capability to retain and share analysis programming scripts, backed up within the IIP.
The key deliverable beyond creating the platform and assuring robust governance was the completion of data linkage studies, pertinent to the clinical community, to test the agility and Infection Intelligence: driving patient outcomes JAC robustness of the IIP to inform national policy and antimicrobial prescribing practice. This has been delivered through a series of studies under two broad themes: (i) intended and unintended effects of antimicrobial stewardship and infection management intervention; and (ii) infection risk factors and clinical outcomes. Table 2 summarizes key studies that provide: reassurance to the clinical community as we seek to safely reduce antimicrobial use; national quantification of clinical outcomes following a healthcare-associated infection (HAI); and application of data at scale to identify and quantify risks associated with infection to These data have been disseminated through national and local networks. The output is now being used to design and test a clinical decision support tool that will enable clinicians to identify patients, at the point of prescribing, who are at higher risk of resistance in pathogens causing suspected UTI and thereby optimize initial antimicrobial treatment.
Changes in HAI outcome over time 19 Surveillance of Clostridium difficile infection (CDI) in Scotland monitors trends in the number of new cases; however, there is no mortality information. This study examined mortality trends of CDI and established risk factors associated with death.
There was a decrease in all-cause mortality within 30 days of diagnosis of CDI between 2009 and 2013 with a yearon-year decrease in case fatality. Older patients, those with a greater number of illnesses, and certain specific conditions, such as lung disease, liver disease and malignancy, were also associated with increased mortality.
Further work focused on identifying those factors associated with increased survival will support quality improvement initiatives to enhance the clinical care of patients with CDI and assure better clinical outcomes.
Association between antimicrobial exposure and HAI risk 20 The contribution of any antimicrobial, but particularly broad-spectrum antimicrobials such as cephalosporins, fluoroquinolones, co-amoxiclav and clindamycin, is known to be associated with a higher risk of CDI but the temporal and cumulative association between community use of antimicrobials and community-acquired CDI was not well described.
Exposure to any antimicrobial, but especially high-risk broad-spectrum antimicrobials, in the previous 6 months increased the odds of communityacquired CDI. Individuals with 29 DDDs of high-risk antimicrobial had an OR of 17.9 (95% CI 7.6-42.2) compared with no antimicrobials. The elevated risk following high-risk antimicrobials was still present 4-6 months after treatment [OR 2.6 (1.7-3.9)]
These findings have been disseminated thorough national and local networks, presented internationally and now published. These data are now being used to generate risk models to create a decision-support tool, ready for testing in primary care in 2018. The outcome will be better assessment of the benefit and risk of treatment with any specific antimicrobials. a More information is available at http://www.isdscotland.org/Health-Topics/Health-and-Social-Community-Care/Infection-Intelligence-Platform/ Study-Outputs.
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inform development of patient-centred clinical decision tools. This evidence is shared with the clinical community through SAPG, the IIP web site, regular newsletters and publication/presentation at international meetings (Table 2) . 6 Platform development and evidence generation has been underpinned by two components: a skills development programme for analytical and statistical staff supported through a joint academic-NHS network to build capability and capacity in infection informatics, and a clinical engagement and communication strategy to build awareness and knowledge of the IIP potential in supporting infection management and control.
Discussion
In Scotland taking a national perspective to infection informatics was logical given: the population size (5.3 million); a national, clinically led approach to antimicrobial stewardship and infection control, and our ability to capture comprehensive healthcare activity for all citizens. IIP sought to build on earlier Scottish experiences gained in diabetes through the Scottish Care InformationDiabetes Collaboration (SCI-DC), 9 a national collaboration that has successfully supported this community in providing and improving patient care, screening services and data for improvement. 10 Previously, Scottish infection publications mainly involved small-scale studies 11, 12 working with local NHS Health Board datasets but the infection community wished to maximize use of existing data to replicate such studies nationally. This desire, coupled with the evolving national and international health policy frameworks, recognizing the role of health informatics, provided the environment to articulate the benefits of investing in a national IIP which has enabled:
• better identification of the intrinsic and extrinsic risk factors for, and outcomes from, infection • better clinical decision making through enhanced intelligence on best practice • more rapid, effective identification of unintended consequences of antimicrobial misuse • improved measurement of health intervention impact on patient outcomes • enhanced evidence base to inform policy.
Central to our success has been clinical engagement and designated, resourced, clinical leadership as a component of the programme. This leadership has ensured that the IIP is aligned with clinical priorities and had a clear translational pathway to impact. Evidence generation from the exemplar studies is already shaping clinical practice (Table 2 ). Moving forward, clinicians' expectations of IIP intelligence are 2-fold: incorporation into clinical decision tools available at the point of care to inform management of individual patient episodes, and timely tailored information resources, well visualized and clinically meaningful, to drive quality improvement.
Future expansion of the range of datasets available through the IIP must address the current absence of both national patientlevel hospital prescribing data and laboratory data, beyond microbiology. Both these gaps are recognized in our eHealth and informatics strategies for Scotland. 13, 14 A plan for rollout of Hospital Electronic Prescribing has been secured and the challenge of laboratory datasets is acknowledged as a priority for action. More collegiate working across NHS, academia and industry should be part of future solutions to enable more rapid innovation in data collation and analytics to improve health outcomes. Such an approach will also enable efficient utilization of expanding data streams being generated through technology advancements, including next-generation sequencing, diagnostics and behavioural risk factors.
Encouragingly, we are not alone in the effort to build better intelligence and utilize routine data and record linkage to improve infectious disease surveillance. 2, 15, 16 Like others we have found that the generation and use of indicators (AMR, antimicrobial use) at a population/geographical level, accessible to all stakeholders, is a strong foundation to identify an agenda for patient-level analysis and a move towards point-of-care clinical decision support tools. Our 'build and test phase' has identified a number of key enablers, potentially transferable to other healthcare systems: government/ policy support; unique patient identifier; strong clinical engagement and leadership; collaborative academic research; and technological 'know how' with proportionate information governance. We are part way along our IIP journey and have begun to increase our responsiveness to address important clinical questions that could be answered through a data linkage approach. We hope our shared experience will inform and encourage others to embark upon this journey and catalyse opportunities for global collaboration.
